Dr. Alexander “Sandro” Sulakvelidze
received his formal training in microbiology in the former Soviet
Union, including a B.A. from Tbilisi State University, a Ph.D. from
Tbilisi State Medical University, and specialized training at the
Engelhard Institute of Molecular Biology, Russian Academy of Sciences,
Moscow, Russia, and the
University of Maryland School of Medicine, Baltimore, Maryland, USA.
Dr. Sulakvelidze’s research interests are in the broad areas
of emerging infectious diseases, molecular epidemiology, pathogenesis
of diseases caused by bacterial enteric pathogens, bacterial toxins,
and phage therapy. One of the major focuses in Dr. Sulakvelidze’s
research are studies of the potential usefulness of bacteriophages in
preventing and treating infectious diseases caused by multidrug
resistant bacteria. Dr. Sulakvelidze has published extensively on the
subject of phage therapy, and he is the author of one issued and
several pending patents related to that field. He also co-edited
(with Dr. Elizabeth Kutter) a major
book about
bacteriophages. Dr. Sulakvelidze’s phage therapy research has been
featured in several magazines and newspapers (including the Los
Angeles Times, ASM News, Genetic Engineering News, Washington Techway,
US News & World Report, Newsweek, Science, Smithsonian, and
Wired), and in various radio programs and television
documentaries (including National Public Radio’s Science Friday and
Tributaries programs, BBC Radio and Voice of America radio programs,
and a BBC Horizon television documentary about phage therapy). Dr.
Sulakvelidze serves as an ad hoc reviewer on such journals as
Antimicrobial Agents and Chemotherapy, Applied and Environmental
Microbiology, Clinical and Experimental Dermatology, FEMS
Immunology and Medical Microbiology, Food
Microbiology, and the Journal of Clinical
Microbiology, and for several funding agencies, including
the Binational Agricultural Research and Development Fund, Civilian
Research and Development Foundation, International Science and
Technology Center, and National Institutes of Health.
Contact Dr.
Sulakvelidze at
asulakvelidze@intralytix.com
